Email this article Regulatory adaptive status in determining the effectiveness of treatment with bisoprololum and nebivololum in patients with paroxysmal atrial fibrillation and hypertension
- Authors: Eremina M.A1, Tregubov V.G1, Pokrovskiy V.M1
-
Affiliations:
- Kuban State Medical University of the Ministry of Health of the Russian Federation
- Issue: Vol 9, No 1 (2018)
- Pages: 10-16
- Section: Articles
- URL: https://journals.rcsi.science/2221-7185/article/view/45931
- DOI: https://doi.org/10.26442/2221-7185_2018.1.10-16
- ID: 45931
Cite item
Full Text
Abstract
Increase in mortality from cardiovascular causes, systemic thromboembolism, congestive heart failure, increased frequency of hospitalization and deterioration in quality of life is associated with atrial fibrillation (AF). Essential hypertension (EH) is the most common cause of AF. To prevent recurrence of AF in patients with hypertension b-blockers (b-AB) can be used. Taking into account the possible effect of multidirectional b-AB on the functional condition of the body, in order to determine the effectiveness of therapy, it is advisable to apply a quantitative assessment of the regulatory-adaptive status (RAS). Goal - compare the effectiveness of bisoprololum and nebivololum in patients with paroxysmal AF and EH, given their impact on the RAS. Materials and methods. 50 patients with AF against the background of EH of stages II-III were randomized into two groups for treatment with bisoprololum (5.4±1.8 mg/day, n=25) or nebivololum (5.6±1.6 mg/day, n=25). As part of combination therapy, patients were administered lisinoprilum (14.2±3.8 and 14.3±3.7 mg/day), when required also atorvastatinum (19.1±3.7 and 18.8±4.4 mg/day), acetylsalicylic acid (90.0±4.6 and 91.2±4.1 mg/day), respectively. Initially and in 6 months, the following was done: quantitative assessment of the RAS (cardio-respiratory synchronism test), echocardiography, triplex scanning of brachiocephalic arteries, treadmill test, six-minute walk test, daily monitoring of blood pressure and electrocardiogram, subjective assessment of the quality of life. Results. Both drug regimens comparably suppressed arrhythmia, controlled hypertension, improved the structural and functional condition of the heart. The use of nebivololum positively affected the RAS, to a greater extent increased exercise capacity and improved the quality of life. Conclusion. In patients with paroxysmal AF against the background of EH of stages II-III, the use of nebivololum as part of combination therapy may be preferable to bisoprololum due to its positive impact on the RAS.
Full Text
##article.viewOnOriginalSite##About the authors
M. A Eremina
Kuban State Medical University of the Ministry of Health of the Russian Federation
Email: marina_eremina@inbox.ru
аспирант каф. нормальной физиологии 350063, Russian Federation, Krasnodar, ul. Sedina, d. 4
V. G Tregubov
Kuban State Medical University of the Ministry of Health of the Russian Federation
Email: vgtregubov@mail.ru
д-р мед. наук, ассистент каф. терапии №2 350063, Russian Federation, Krasnodar, ul. Sedina, d. 4
V. M Pokrovskiy
Kuban State Medical University of the Ministry of Health of the Russian Federation
Email: pokrovskyvm@gmail.com
д-р мед. наук, проф., зав. каф. нормальной физиологии 350063, Russian Federation, Krasnodar, ul. Sedina, d. 4
References
- Fuster V, Ryden L.E, Cannom D.S et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). JACC 2006; 48 (6): 854-906.
- Camm A.J, Kirchhof P, Lip G.Y.H. et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31 (8): 2369-429.
- Wann S, Curtis A.B, January C.T. et al. 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline). A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123 (5): 104-23.
- Оганов Р.Г., Салимов В.А., Бокерия Л.А. и др. Клинические рекомендации по диагностике и лечению пациентов с фибрилляцией предсердий. Вестн. аритмологии. 2010; 59: 53-77.]
- Kirchhof P, Bax J, Blomstrom-Lundquist C et al. Early and comprehensive management of atrialfibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference “Research perspectives in AF”. Eur Heart J 2009; 30 (24): 2969-77.
- CIBIS III trial: bisoprolol treatment for CHF leads to 46% reduction in sudden death after one year. Cardiovascular J South Africa 2006; 17 (5): 278.
- Bristow M.R. b-adrenergic receptor blockade in chronic heart failure. Circulation 2000; 101 (5): 558-69.
- Lopez-Sendon J, Swedberg K, McMurray J et al. Expert consensus document on b-adrenergic receptor blockers: the task force on b-blockers of the European Society of cardiology. Eur Heart J 2004; 25 (15): 1341-62.
- Тарасов А.В. Вопросы безопасности антиаритмической терапии. Consilium Medicum. 2014; 16 (10): 44-9.
- Покровский В.М. Сердечно-дыхательный синхронизм в оценке регуляторно-адаптивных возможностей организма. Краснодар: Кубань-Книга, 2010
- Ломакин А.И., Шнайдер Н.А., Садыкова А.В., Стручков П.В. Актуальные вопросы функциональной диагностики. Медицина экстремальных ситуаций. 2011; 4 (38): 111-8
- Умрюхин Е.А., Быкова Е.В., Климина Н.В. Вегетативный тонус и энергозатраты у студентов в процессе результативной учебной деятельности. Вестн. РАМН. 1999; 6: 47-51
- Krause T, Lovibond K, Caulfield M et al. Managemant of hypertension: summary of NICE guildelines. Brit Med J 2011; 343. doi: 10.1136/bmj.d4891
- Houle S.K, Padwal R, Tsuyuki R.T. The 2012-2013 Canadian Hypertension Education Program (CHEP) guidelines for pharmacists: An update. Canаdian Pharma J 2013; 146 (3): 146-50.
- Недогода С.В., Ледяева А.А., Чумачок Е.Г. и др. b-Адреноблокатор небиволол с позиции решения проблем лечения артериальной гипертензии в условиях реальной клинической практики. Справочник поликлинического врача. 2012; 1: 10-4.
- Минушкина Л.О. Бисопролол: возможности в лечении артериальной гипертонии. Кардиология. 2012; 52 (6): 80-5.
- Sule S.S, Frishman W. Nebivolol: new therapy update. Cardiol Rev 2006; 14 (5): 259-64.
- Покровский В.М., Потягайло Е.Г., Абушкевич В.Г., Похотько А.Г. Сердечно-дыхательный синхронизм: выявление у человека, зависимость от свойств нервной системы и функциональных состояний организма. Успехи физиологических наук. 2003; 34 (3): 68-77
- Трегубов В.Г., Покровский В.М., Канорский С.Г. Количественная оценка регуляторно-адаптивного статуса в определении тяжести хронической сердечной недостаточности. Клин. медицина. 2012; 8: 32-5.
- Канорский С.Г., Трегубов В.Г., Покровский В.М. Преимущества терапии квинаприлом у пациентов с артериальной гипертензией и хронической сердечной недостаточностью I-II функционального класса и сохраненной фракцией выброса левого желудочка. Кардиология. 2012; 52 (4): 31-8.
